Slide background
TAmiRNA – Triple A research and development of RNA diagnostics and therapeutics
Slide background
TAmiRNA – Introducing personalized medicine to Aging
Slide background
TAmiRNA – Harnessing the power of microRNAs for development of innovative diagnostic and therapeutic tools
Slide background
TAmiRNA – Helping to enhance your stability and quality of life with advanced age


Dr. Matthias Hackl

Matthias Hackl, PhD

CEO and co-founder

Matthias Hackl graduated in the area of Biotechnology from the University of Natural Resources and Life Sciences Vienna (Boku) in 2012. His studies of microRNA function in mammalian cell lines and model systems of Ageing involved rotations through labs at the University of Georgia and Minnesota in the United States as well as University Bielefeld in Germany.  Matthias has won two private company grants for developing applications of PCR and Flow Cytometry based microRNA quantification tools and was honored by the Austrian Association of Molecular Life Sciences and Biotechnology for his achievements during his PhD. He has authored 30 publications and two book chapters in the field of microRNA biology and held a one-year PostDoc position in microRNA-based cell engineering at the Vienna Institute of Biotechnology before joining TAmiRNA. Matthias Hackl is also co-founder of Remute Bio GmbH, founded in 2016.

Otto Kanzler

Otto Kanzler

CFO and co-founder

Otto Kanzler has more than 30 years experience in process- and business development in the biotech industry. Since 2007 he is serving as Management Consultant for production and technology-development for biotech- and pharma- industry, specified for strategic and economic issues. He is a serial entrepreneur having founded and co-founded several companies, all of which are still active - CEO / CFO of Remute Bio GmbH (founded 2016), co-founder and interim CEO / CFO of Phoenestra GmbH (founded 2015), Advisor of DirectSens GmbH (since 2015), co-founder and CFO of Syconium Lactic Acid GmbH (founded 2014),  co-founder and CFO of TAmiRNA GmbH (founded 2012),  co-founder and CEO of Evercyte GmbH und Chorus GmbH, (both founded 2011). Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria (1981-1993).



Dr. Johannes Grillari

Johannes Grillari, PhD assoc Prof.

Scientific advisor and co-founder

Johannes Grillari has more than 10 years of experience as a group leader in cellular and molecular aging research. Since 2006 he is associate professor at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria. He did his PhD degree between 1996 and 1999 on senescence of endothelial cells and worked as a visiting scientist at the University of Dundee, Scotland, UK. He has authored and co-authored more than 63 scientific articles and book chapters, 6 patents, and was invited as speaker more than 70 times to international meetings. Furthermore, Johannes Grillari is co-founder and CSO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (founded 2015) and co-founder and scientific advisor of Remute Bio GmbH (2016).

Dr. Regina Grillari

Regina Grillari, PhD assoc Prof.

Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009.  In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).

Wolfgang Woloszczuk, PhD Univ. Prof.

Scientific Advisor

As a former professor of the Medical University of Vienna, Prof. Woloszczuk was involved in the development of numerous biochemical biomarkers and diagnostic tests for bone diseases. He co-founded the Biomedica GmbH, which specializes in the development and commercialization of diagnostic products.

Prof. Woloszczuk supports TAmiRNA in strategic decisions in respect to development and marketing of its novel biomarker tests.

Eric Schiffer, PhD

Scientific advisor

Eric Schiffer has long-standing expertise in the development of multi-parametric biomarkers using mass spectroscopic methods. As the former head of clinical development at Mosaiques Diagnostics, Eric headed a group that successfully developed protein biomarkers eventually reaching FDA approval. Within TAmiRNA,

Eric Schiffer provides support during planning and conduction of clinical studies and technical assay development in order to ensure compliance with regulatory standards.

Peter Pietschmann PhD med., assoc. Prof.

Scientific advisor

Peter Pietschmann is Deputy Head at the Department of Pathophysiology at the Medical University of Vienna since 2006 after being appointed as Associate Professor in 2002. His group is conducting research on the pathophysiology of bone fragility and the relation of bone strength to gene expression. He has published 169 papers in peer-reviewed journals in the area of Osteoporosis and was honored with several awards. Dr. Pietschmann is currently serving as President of the Austrian Society of Bone and Mineral Research, and former president of the Austrian Society of Geriatrics & Gerontology.

Peter Pietschmann supports TAmiRNA in scientific and strategic decisions in developing novel biomarkers for risk assessment in osteoporosis.

Heinz Redl PhD Univ. Prof.

Scientific Advisor

Since 1998 Heinz Redl is the director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology. In his group, Dr. Redl has pioneered research in the field of tissue/bone regeneration and has lead the development of innovative approaches to bone healing.

Prof. Redl assists in TAmiRNA in the design and conduction of pre-clinical trials.


Click here for your personalized microRNA service offer!